FDA approves first at‐home brain therapy for resistant MDD
The Food and Drug Administration (FDA) on Jan. 12 announced its approval of the first prescription, physician‐directed, at‐home brain neuromodulation therapy as an adjunctive treatment for adults with major depressive disorder (MDD) who failed to achieve satisfactory improvement from at least one previous antidepressant.
Authors
- Valerie A. Canady
Publication Details
- Journal
- Mental Health Weekly
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1002/mhw.34723
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00